Viking Phase II Update Shows Sustained Response After Treatment’s End

 
• By Joseph Haas

Currently running a Phase IIb NASH trial with VK2809, Viking reported at EASL that 16-week data in a Phase II study of NAFLD patients showed sustained liver fat reduction after treatment ended.

SC2008_Fatty Liver_274834199_1200.jpg
Viking thinks its THR beta agonist for NASH could be best in class

More from Clinical Trials

More from R&D